CoChat

The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma

Open access
Biernacka, Anna, Tsongalis, Peter D., Peterson, Jason D., de Abreu, Francine B., Black, Candice C., Gutmann, Edward J., Liu, Xiaoying, Tafe, Laura J., Amos, Christopher I., Tsongalis, Gregory J. · 2016 · Cancer Genetics
Cited by 120

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

KRAS mutant non-small cell lung cancers (NSCLCs) vary in clinical outcome depending on which specific KRAS mutation is present. Shorter progression free survival has been associated with KRAS variants G12C and G12V. Cell lines with these variants depend to a greater extent on the RAS/RAF/MEK/ERK signaling pathway and become more susceptible to MEK inhibition. Because different KRAS mutations may lead to altered drug sensitivity, we aimed to determine specific KRAS mutation status in a NSCLC patient cohort at our institution. A total of 502 NSCLC samples were screened for somatic mutations using the 50 gene AmpliSeq™ Cancer Hotspot Panel v2 (CHPv2). However only samples positive for variants in the KRAS gene were included in this study. Variants identified in the KRAS genes were curated using publicly available databases. The overall mutation rate in the KRAS gene was 32.7% (164/502). The most common KRAS mutations were G12C (41%), G12V (19%), and G12D (14%) along with less frequent variants. After re-mining our sequencing data, we found that more than a half of our KRAS mutant NSCLC patients could potentially benefit from the addition of a MEK inhibitor such as selumetinib to standard chemotherapeutic agents. Due to mutated KRAS, these patients will likely fail traditional anti-EGFR therapies but be eligible for newer combination therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cancergen.2016.03.001

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 120

Metadata

Authors
Biernacka, A., Tsongalis, P. D., Peterson, J. D., de Abreu, F. B., Black, C. C., Gutmann, E. J., Liu, X., Tafe, L. J., Amos, C. I., & Tsongalis, G. J.
Venue
Cancer Genetics
Publisher
Elsevier BV
Published
2016-05
Volume
209
Issue
5
Pages
195-198
ISSN
2210-7762 (ISSN-L)
OpenAlex
W2305475210
Cited by
120
References
5
FWCI
0.79
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma. https://app.cochat.ai/papers/10.1016/j.cancergen.2016.03.001
The paper
Biernacka, A., Tsongalis, P. D., Peterson, J. D., de Abreu, F. B., Black, C. C., Gutmann, E. J., Liu, X., Tafe, L. J., Amos, C. I., & Tsongalis, G. J. (2016). The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma. Cancer Genetics. https://doi.org/10.1016/j.cancergen.2016.03.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.